Despite Fast-paced Momentum, Century Therapeutics (IPSC) Is Still a Bargain StockZacks Investment Research • 07/15/25
Century Therapeutics (IPSC) Is Attractively Priced Despite Fast-paced MomentumZacks Investment Research • 06/25/25
Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 CongressGlobeNewsWire • 05/28/25
Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top EstimatesZacks Investment Research • 05/16/25
Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 05/15/25
Century Therapeutics, Inc. (IPSC) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 05/01/25
Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual MeetingGlobeNewsWire • 04/28/25
Century Therapeutics (IPSC) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 03/25/25
Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 03/19/25
Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 03/19/25
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare ConferenceGlobeNewsWire • 11/26/24
Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/05/24
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewsWire • 11/05/24
Century Therapeutics to Present at Guggenheim's Inaugural Healthcare Innovation ConferenceGlobeNewsWire • 11/04/24
Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific OfficerGlobeNewsWire • 09/26/24
Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/08/24
Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewsWire • 08/08/24
Century Therapeutics (IPSC) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 07/09/24
Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101Seeking Alpha • 06/20/24
Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual MeetingGlobeNewsWire • 06/03/24
Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/09/24
Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewsWire • 05/09/24
Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitGlobeNewsWire • 04/23/24
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade TherapeuticsGlobeNewsWire • 04/11/24